- Home » News and EventsPage 17
NEWS & EVENTS
Our newest offerings and capabilities. Recent investments in network capacity, new and expanded services and expertise. Upcoming conferences and events.
Technologies to Enhance Cell Line Productivity and Expand Antibody-Drug Conjugate Therapeutic Window to be Presented by Catalent Biologics at PEGS
Aug 25, 2020
Catalent today announced that two Catalent Biologics experts will present at the upcoming 16th Annual PEGS Boston Virtual Conference & Expo, taking place between Aug. 31 – September 4, 2020.
Catalent Signs Agreement with AstraZeneca to Expand Manufacturing Support for COVID-19 Vaccine AZD1222
Aug 24, 2020
Catalent Cell & Gene Therapy will provide drug substance manufacturing for the University of Oxford’s adenovirus vector-based vaccine at Catalent’s Harmans, Maryland gene therapy manufacturing facility.
Catalent to Discuss a Scalable Gene Therapy Manufacturing Process and Early Development Considerations for Orphan Drugs at Upcoming Industry Congress
Aug 18, 2020
Catalent today announced it will present at the upcoming World Orphan Drug Congress Annual Meeting, which will take place virtually on Aug. 24 – 26, 2020.
Post-Brexit European Clinical Supply Solutions to be Discussed by Catalent at Upcoming Forum
Aug 11, 2020
Catalent today announced that Paul Ingram, Ph.D., Global Director, Strategic Development and Innovation, will present at the upcoming conference, ‘Clinical Trial Supply Forum’.
Catalent Gene Therapy Facility Receives FDA Approval as an Additional Manufacturing Site for AveXis’ Gene Therapy
Aug 6, 2020
Catalent today announced that it was approved by the U.S. FDA to produce commercial drug substance intermediate for AveXis’ spinal muscular atrophy gene therapy.
Catalent Adds Potent Manufacturing Capabilities at its Buenos Aires, Argentina Site
Aug 4, 2020
Catalent today announced that it will expand its Argentinian site in Loma Hermosa, Buenos Aires. The expansion will be segregated and designed to handle cytotoxic and highly active products for prescription softgel manufacturing.
Catalent Enters into Strategic Partnership with Editas Medicine to Support Gene Editing Medicine Pipeline
Jul 29, 2020
Catalent will support the development, manufacturing, and clinical supply of Editas Medicine’s portfolio of in vivo CRISPR medicines and engineered cell medicines.
Catalent Biologics’ Executive to Discuss Manufacturing Scale-up During a Pandemic
Jul 22, 2020
Catalent today announced that Mike Riley, Region President, Biologics, North America, will present at the upcoming Disease Prevention & Control Summit, taking place virtually on July 28 – 29, 2020.
Catalent Biologics to Invest $30 Million to Create European Clinical Manufacturing Center of Excellence in Limoges, France
Jul 21, 2020
Catalent today announced that it plans to invest $30 million (€27 million) at its facility in Limoges, France, to create a European center of excellence for clinical biologics formulation development and drug product fill-finish services.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.